1. Market Research
  2. > Pharmaceutical Market Trends
  3. > SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014

SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 33 pages

SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014’, provides an overview of the SymBio Pharmaceuticals Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SymBio Pharmaceuticals Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of SymBio Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of SymBio Pharmaceuticals Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the SymBio Pharmaceuticals Limited’s pipeline products

Reasons to buy

- Evaluate SymBio Pharmaceuticals Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of SymBio Pharmaceuticals Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the SymBio Pharmaceuticals Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of SymBio Pharmaceuticals Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of SymBio Pharmaceuticals Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of SymBio Pharmaceuticals Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

SymBio Pharmaceuticals Limited - Product Pipeline Review - 2014
Table of Contents

SymBio Pharmaceuticals Limited Snapshot 4
SymBio Pharmaceuticals Limited Overview 4
Key Information 4
Key Facts 4
SymBio Pharmaceuticals Limited - Research and Development Overview 5
Key Therapeutic Areas 5
SymBio Pharmaceuticals Limited - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
SymBio Pharmaceuticals Limited - Pipeline Products Glance 11
SymBio Pharmaceuticals Limited - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
SymBio Pharmaceuticals Limited - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
SymBio Pharmaceuticals Limited - Drug Profiles 14
bendamustine hydrochloride 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
rigosertib sodium 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
SyB-0702 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
SymBio Pharmaceuticals Limited - Pipeline Analysis 21
SymBio Pharmaceuticals Limited - Pipeline Products by Target 21
SymBio Pharmaceuticals Limited - Pipeline Products by Route of Administration 22
SymBio Pharmaceuticals Limited - Pipeline Products by Molecule Type 23
SymBio Pharmaceuticals Limited - Pipeline Products by Mechanism of Action 24
SymBio Pharmaceuticals Limited - Recent Pipeline Updates 25
SymBio Pharmaceuticals Limited - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
forigerimod 30
SymBio Pharmaceuticals Limited - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables

SymBio Pharmaceuticals Limited, Key Information 4
SymBio Pharmaceuticals Limited, Key Facts 4
SymBio Pharmaceuticals Limited - Pipeline by Indication, 2014 6
SymBio Pharmaceuticals Limited - Pipeline by Stage of Development, 2014 7
SymBio Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2014 8
SymBio Pharmaceuticals Limited - Partnered Products in Pipeline, 2014 9
SymBio Pharmaceuticals Limited - Partnered Products/ Combination Treatment Modalities, 2014 10
SymBio Pharmaceuticals Limited - Phase II, 2014 11
SymBio Pharmaceuticals Limited - Phase I, 2014 12
SymBio Pharmaceuticals Limited - Preclinical, 2014 13
SymBio Pharmaceuticals Limited - Pipeline by Target, 2014 21
SymBio Pharmaceuticals Limited - Pipeline by Route of Administration, 2014 22
SymBio Pharmaceuticals Limited - Pipeline by Molecule Type, 2014 23
SymBio Pharmaceuticals Limited - Pipeline Products by Mechanism of Action, 2014 24
SymBio Pharmaceuticals Limited - Recent Pipeline Updates, 2014 25
SymBio Pharmaceuticals Limited - Discontinued Pipeline Products, 2014 30

List of Figures

SymBio Pharmaceuticals Limited - Pipeline by Top 10 Indication, 2014 6
SymBio Pharmaceuticals Limited - Pipeline by Stage of Development, 2014 7
SymBio Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2014 8
SymBio Pharmaceuticals Limited - Partnered Products in Pipeline, 2014 9
SymBio Pharmaceuticals Limited - Pipeline by Top 10 Target, 2014 21
SymBio Pharmaceuticals Limited - Pipeline by Top 10 Route of Administration, 2014 22
SymBio Pharmaceuticals Limited - Pipeline by Top 10 Molecule Type, 2014 23
SymBio Pharmaceuticals Limited - Pipeline Products by Top 10 Mechanism of Action, 2014 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.